StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Non-GAAP total revenues by Quarter

Non-GAAP total revenues (historical through FY2021, $M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Non-GAAP total revenues: $2,073M in Q4 2021, up 27.4% from a year earlier. That is the highest of the 21 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2021
2,073
Period ended Dec 31, 2021
Change on a year earlier
+27.4%
1,627 in Q4 2020
History
21 quarters
Since Q4 2016
Sources
17
Documents cited below

Where the Q4 2021 figure comes from

“|| Non-GAAP total revenues | $ | 2,072.6 | $ | 1,626.9 | $ | 7,573.4 | $ | 6,202.8”

Source: Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗

Reported in Form 8-K EX-99.1 Earnings Releases (FY2016–FY2021).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP total revenues (historical through FY2021, $M) ($M)Year on yearSource
Q4 2021Dec 31, 20212,073+27.4%Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗
Q3 2021Sep 30, 20211,984+29.2%Form 8-K (ex-991_q32021.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 20211,793+17.6%Form 8-K (ex-991_q22021.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 20211,723+13.7%Form 8-K (ex-991_q12021.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 20201,627+29.4%Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗
Q3 2020Sep 30, 20201,536+61.7%Form 8-K (ex-991_q32021.htm, filed 2021-11-02) ↗
Q2 2020Jun 30, 20201,525+62.0%Form 8-K (ex-991_q22021.htm, filed 2021-07-29) ↗
Q1 2020Mar 31, 20201,515+76.5%Form 8-K (ex-991_q12021.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 20191,258+44.6%Form 8-K (ex-991_q42020.htm, filed 2021-02-01) ↗
Q3 2019Sep 30, 2019950+21.2%Form 8-K (ex-991q32020.htm, filed 2020-10-29) ↗
Q2 2019Jun 30, 2019941+25.3%Form 8-K (ex-991q22020.htm, filed 2020-07-30) ↗
Q1 2019Mar 31, 2019858+34.3%Form 8-K (ex-991q12020.htm, filed 2020-04-29) ↗
Q4 2018Dec 31, 2018869+39.6%Form 8-K (ex-991q42019.htm, filed 2020-01-30) ↗
Q3 2018Sep 30, 2018784+42.0%Form 8-K (ex-991q32019.htm, filed 2019-10-30) ↗
Q2 2018Jun 30, 2018751+45.3%Form 8-K (ex-991_q22019.htm, filed 2019-07-31) ↗
Q1 2018Mar 31, 2018639+32.5%Form 8-K (ex-991_q12019.htm, filed 2019-04-30) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Non-GAAP total revenues ($M), quarterly Q4 2016–Q4 2021 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-rev

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.